News Releases

Date Title and Summary Additional Formats
Toggle Summary Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments
-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded Process Development Facility and Services -- TUSTIN, Calif. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices ,
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , Dec. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies,
View HTML
Toggle Summary Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2020 After Market Close on December 9, 2019
TUSTIN, Calif. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies,
View HTML
Toggle Summary Avid Bioservices Names Richard Richieri as Chief Operations Officer
Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing Operations Experience   TUSTIN, Calif. , Oct. 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO)
View HTML
Toggle Summary Avid Bioservices Announces Completion of Expansion of Process Development Capabilities and Laboratory Infrastructure
Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories   TUSTIN, Calif. , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve
View HTML
Toggle Summary Avid Bioservices Announces Termination of Stockholder Rights Plan
TUSTIN, Calif. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical
View HTML
Toggle Summary Avid Bioservices Reports Financial Results for First Quarter Fiscal 2020 and Recent Developments
-- Achieved First Quarter Revenue of $15.3 Million ; Reaffirms Fiscal 2020 Projected Revenue of $64 to $67 Million -- -- Signed Two Contract Manufacturing Agreements with New and Existing Customers -- TUSTIN, Calif. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices , Inc. (NASDAQ:CDMO)
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical
View HTML
Toggle Summary Avid Bioservices to Report Financial Results For First Quarter of Fiscal Year 2020 After Market Close on September 5, 2019
TUSTIN, Calif. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies,
View HTML
Toggle Summary Avid Bioservices Announces Appointment of Catherine Mackey, Ph.D. to Board of Directors
TUSTIN, Calif. , July 26, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies,
View HTML
Toggle Summary Avid Bioservices Enters into Contract Manufacturing Agreements with New and Existing Customers
Company Signs Top Ten Global Pharmaceutical Company as New Client and Expands Relationship with Existing Biotechnology Company Customer Agreements Include Process Transfer, Process Development and Clinical Manufacturing for Novel Therapeutic Candidates TUSTIN, Calif.
View HTML
Toggle Summary Avid Bioservices Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2019 and Recent Developments
  -- Achieved Fourth Quarter Revenue of $17.1 Million , an Increase of 146%  Compared to Prior Year Quarter -- -- Generated Income From Continuing Operations During the Fourth Quarter of Fiscal 2019 -- -- Increasing Demand from Customers Expected to Drive Continued Revenue Growth into 2020 --
View HTML
Toggle Summary Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2019 After Market Close on June 27, 2019
TUSTIN, Calif. , June 24, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif. , June 05, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Participate at BIO International Convention 2019
-- Company to Provide Insight on Key CDMO Industry Topics through Podium Presentation, Panel Discussion and Executive Interview as Part of Convention’s BioProcess  International Theater -- -- Corporate Booth to Highlight Company’s CDMO Service Offerings and State-of-the-Art Clinical and Commercial
View HTML